Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Comparison of adverse events of erlotinib with those of gefitinib in patients with non-small cell lung cancer: a case-control study in a Japanese population.

Suzumura T, Kimura T, Kudoh S, Umekawa K, Nagata M, Tanaka H, Mitsuoka S, Yoshimura N, Kira Y, Hirata K.

Osaka City Med J. 2012 Jun;58(1):25-34.

PMID:
23094511
2.

Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.

Suzumura T, Kimura T, Kudoh S, Umekawa K, Nagata M, Matsuura K, Tanaka H, Mitsuoka S, Yoshimura N, Kira Y, Nakai T, Hirata K.

BMC Cancer. 2012 Dec 4;12:568. doi: 10.1186/1471-2407-12-568.

3.

Polymorphisms of CYP2D6 gene and gefitinib-induced hepatotoxicity.

Takimoto T, Kijima T, Otani Y, Nonen S, Namba Y, Mori M, Yokota S, Minami S, Komuta K, Uchida J, Imamura F, Furukawa M, Tsuruta N, Fujio Y, Azuma J, Tachibana I, Kumanogoh A.

Clin Lung Cancer. 2013 Sep;14(5):502-7. doi: 10.1016/j.cllc.2013.03.003. Epub 2013 May 9.

PMID:
23664723
4.

Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy.

Kim ST, Uhm JE, Lee J, Sun JM, Sohn I, Kim SW, Jung SH, Park YH, Ahn JS, Park K, Ahn MJ.

Lung Cancer. 2012 Jan;75(1):82-8. doi: 10.1016/j.lungcan.2011.05.022.

PMID:
21684626
5.

Differences in adverse events between 250 mg daily gefitinib and 150 mg daily erlotinib in Japanese patients with non-small cell lung cancer.

Togashi Y, Masago K, Fujita S, Hatachi Y, Fukuhara A, Nagai H, Sakamori Y, Kim YH, Mio T, Mishima M.

Lung Cancer. 2011 Oct;74(1):98-102. doi: 10.1016/j.lungcan.2011.01.022. Epub 2011 Mar 5.

PMID:
21377230
6.

[Comparative evaluation of adverse reactions between gefitinib and erlotinib treatments in the same patients].

Ohashi Y, Suzuki K, Sakurai M, Shino M, Murakami H, Takahashi T, Yamamoto N.

Gan To Kagaku Ryoho. 2009 Aug;36(8):1327-31. Japanese.

PMID:
19692772
7.

Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.

Kim ST, Lee J, Kim JH, Won YW, Sun JM, Yun J, Park YH, Ahn JS, Park K, Ahn MJ.

Cancer. 2010 Jun 15;116(12):3025-33. doi: 10.1002/cncr.25130.

8.

[Erlotinib in the treatment of advanced non-small-cell lung cancer (NSCLC)].

Tang CH, Liu XQ, Gao HJ, Li JJ, Guo WF, Li XY, Wang WX, Liu B, Qu LL, Wang WW.

Zhonghua Zhong Liu Za Zhi. 2010 Feb;32(2):143-7. Chinese.

PMID:
20403247
9.

Plasma MIP-1beta levels and skin toxicity in Japanese non-small cell lung cancer patients treated with the EGFR-targeted tyrosine kinase inhibitor, gefitinib.

Kimura H, Kasahara K, Sekijima M, Tamura T, Nishio K.

Lung Cancer. 2005 Dec;50(3):393-9. Epub 2005 Sep 8.

PMID:
16153743
10.

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.

Johnson JR, Cohen M, Sridhara R, Chen YF, Williams GM, Duan J, Gobburu J, Booth B, Benson K, Leighton J, Hsieh LS, Chidambaram N, Zimmerman P, Pazdur R.

Clin Cancer Res. 2005 Sep 15;11(18):6414-21.

11.
12.

Efficacy of erlotinib in patients with advanced non-small cell lung cancer: a pooled analysis of randomized trials.

Gao H, Ding X, Wei D, Cheng P, Su X, Liu H, Aziz F, Wang D, Zhang T.

Anticancer Drugs. 2011 Oct;22(9):842-52. doi: 10.1097/CAD.0b013e328349c303. Review.

PMID:
21808188
13.

The administration of gefitinib in patients with advanced non-small-cell lung cancer after the failure of erlotinib.

Grossi F, Rijavec E, Dal Bello MG, Defferrari C, Brianti A, Barletta G, Genova C, Murolo C, Cosso M, Fontanini G, Boldrini L, Truini M, Pronzato P.

Cancer Chemother Pharmacol. 2012 Jun;69(6):1407-12. doi: 10.1007/s00280-012-1848-4. Epub 2012 Feb 21.

PMID:
22349923
14.

United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets.

Cohen MH, Williams GA, Sridhara R, Chen G, McGuinn WD Jr, Morse D, Abraham S, Rahman A, Liang C, Lostritto R, Baird A, Pazdur R.

Clin Cancer Res. 2004 Feb 15;10(4):1212-8.

15.

Comparison of gefitinib and erlotinib efficacies as third-line therapy for advanced non-small-cell lung cancer.

Shao YY, Shau WY, Lin ZZ, Chen HM, Kuo R, Yang JC, Lai MS.

Eur J Cancer. 2013 Jan;49(1):106-14. doi: 10.1016/j.ejca.2012.07.014. Epub 2012 Aug 14.

PMID:
22897841
16.

Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.

Hata A, Katakami N, Yoshioka H, Fujita S, Kunimasa K, Nanjo S, Otsuka K, Kaji R, Tomii K, Iwasaku M, Nishiyama A, Hayashi H, Morita S, Ishida T.

Lung Cancer. 2011 Nov;74(2):268-73. doi: 10.1016/j.lungcan.2011.03.010. Epub 2011 May 6.

PMID:
21529987
17.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y, Nishiwaki Y, Ohe Y, Yang JJ, Chewaskulyong B, Jiang H, Duffield EL, Watkins CL, Armour AA, Fukuoka M.

N Engl J Med. 2009 Sep 3;361(10):947-57. doi: 10.1056/NEJMoa0810699. Epub 2009 Aug 19.

18.

A double-blind, randomised, placebo-controlled phase III intergroup study of gefitinib in patients with advanced NSCLC, non-progressing after first line platinum-based chemotherapy (EORTC 08021/ILCP 01/03).

Gaafar RM, Surmont VF, Scagliotti GV, Van Klaveren RJ, Papamichael D, Welch JJ, Hasan B, Torri V, van Meerbeeck JP; EORTC Lung Cancer Group and the Italian Lung Cancer Project.

Eur J Cancer. 2011 Oct;47(15):2331-40. doi: 10.1016/j.ejca.2011.06.045. Epub 2011 Jul 28.

PMID:
21802939
19.

Erlotinib: new drug. Non small-cell lung cancer: like gefitinib, no established advantage.

[No authors listed]

Prescrire Int. 2006 Jun;15(83):86-9.

PMID:
16764093
20.

Screening for epidermal growth factor receptor mutations in lung cancer.

Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M, Insa A, Massuti B, Gonzalez-Larriba JL, Paz-Ares L, Bover I, Garcia-Campelo R, Moreno MA, Catot S, Rolfo C, Reguart N, Palmero R, Sánchez JM, Bastus R, Mayo C, Bertran-Alamillo J, Molina MA, Sanchez JJ, Taron M; Spanish Lung Cancer Group.

N Engl J Med. 2009 Sep 3;361(10):958-67. doi: 10.1056/NEJMoa0904554. Epub 2009 Aug 19.

Supplemental Content

Support Center